权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Noninvasive Pressure Estimation in Breast Cancer using Ultrasound

使用超声波对乳腺癌进行无创压力估计

基本信息

批准号：
9225468
负责人：
Kenneth Hoyt
金额：
$ 19.97万
依托单位：
UNIVERSITY OF TEXAS DALLAS
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-01-12 至 2018-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9225468
关键词：
Acoustics Adopted Angiogenesis Inhibitors Animal Model Animals Antineoplastic Agents Blood Vessels Breast Cancer Cell Breast Cancer Model Breast Cancer Patient Cancer Patient Cancerous Clinical Management Contrast Media Custom Data Detection Development Drug Delivery Systems Extracellular Space Goals Gold Growth Human Hydrostatic Pressure Image Implant Liquid substance Measurement Measures Methods Microbubbles Monitor Morbidity - disease rate Mus Needles Neoadjuvant Therapy Normal tissue morphology Operative Surgical Procedures Outcome Paclitaxel Patient Monitoring Patients Pharmaceutical Preparations Phase Transition Physiologic pulse Physiological Publishing Research Project Grants Research Proposals Subgroup System Systemic Therapy Techniques Technology Testing Time Tissues Ultrasonic Therapy Ultrasonography Woman anticancer treatment base cancer therapy chemotherapy contrast enhanced experimental study improved in vivo individual patient individualized medicine innovation innovative technologies interstitial intravenous administration lymphatic drainage malignant breast neoplasm nanoDroplet nanoscale new technology next generation novel phase change pressure prevent programs responders and non-responders response technology development time use tumor tumor growth uptake vapor vaporization

项目摘要

PROJECT SUMMARY It is known that breast cancers with high tumor interstitial pressure (TIP) respond poorly to chemotherapy because of poor drug delivery (i.e., the high pressure prevents the drug from entering the tumorous tissue). Recent data suggests TIP is a potentially useful parameter for assessing whether a particular breast cancer will in fact ever respond to systemic anticancer treatment. Moreover, our group has exciting data that would suggest noninvasive pressure estimation in breast cancer tissue can be performed in real-time using a novel contrast agent and custom technology we have termed TIP estimation using US (TIPE-US). The first aim of this project is to develop a monodisperse phase-change contrast agent (PCCA) that is a stabilized liquid nanodroplet under ambient conditions but can be triggered using US energy to undergo a phase transition into a highly echogenic microbubble (MB). Importantly, this phase transition is sensitively governed, and linearly related to, the surrounding hydrostatic fluid pressure. We will then determine the optimal US parameters (energy) required for activating these PCCA while precisely varying the surrounding fluid pressure across a range of physiologically relevant values. A programmable US scanner will be customized to initiate and detect PCCA activation and then convert the US energy used into a corresponding pressure value via lookup tables. In the second aim, we will evaluate the potential of TIPE-US for monitoring early tumor response (or lack thereof) to anticancer therapy using an animal model of breast cancer. The outcome of the proposed experiments will establish whether TIPE-US is a viable new method for measuring intratumoral pressure in cancerous tissue. This innovative technology may ultimately be utilized to both measure TIP in cancer patients and for monitoring treatment in the neoadjuvant setting to differentiate between responders and non-responders, which in turn will allow for better, individualized treatment options to be selected.

项目总结